HAIFA, Israel, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) announced today that it intends, subject to market and other conditions, to offer shares of its common stock and warrants to purchase shares of its common stock in a registered public offering. The shares of common stock and warrants to purchase shares of common stock are being offered as units. Pluristem also intends to grant the underwriters of the offering an option to purchase additional shares of common stock and warrants to cover over-allotments, if any. Pluristem plans to use the proceeds from the offering to conduct clinical trials, research and product development activities and for general corporate purposes, including general working capital purposes. Jefferies & Company, Inc. is acting as sole book-running manager for the proposed offering. Oppenheimer & Co. Inc. is acting as co-lead manager for the proposed offering. Needham & Company, LLC and Maxim Group LLC are acting as co-managers for the proposed offering. In addition, Leader Capital Markets Ltd. is acting as the company's financial advisor in connection with the proposed offering. The securities described above are being offered by Pluristem pursuant to a "shelf" registration statement previously declared effective by the Securities and Exchange Commission (SEC) on October 20, 2011 (File No. 333-177009). A prospectus supplement and an accompanying prospectus will be filed with the SEC in connection with the offering. Before you invest, you should read the prospectus supplement and accompanying prospectus, the registration statement, and the other documents that Pluristem has filed with the SEC for more complete information about Pluristem and this offering. Once filed, copies of the prospectus supplement and accompanying prospectus relating to these securities may be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com. Investors may also obtain these documents for no charge by visiting the SEC's website at www.sec.gov. This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Pluristem Therapeutics Inc.:Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe inflammatory and ischemic disorders. The Pluristem Therapeutics Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6882 This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward looking statements when we discuss our proposed public offering and our plans for use of proceeds from the proposed offering. Any such statements, whether expressed or implied, are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, and other risk factors discussed in the company's Annual Report on Form 10-K for the year ended June 30, 2012 and other documents filed with the Securities and Exchange Commission from time to time. These forward-looking statements represent the company's judgment as of the date of this news release. Except as otherwise required by law, the company disclaims any intent or obligation to update these forward-looking statements.
CONTACT: Pluristem Therapeutics Inc. Daya Lettvin Investor & Media Relations Director Tel: +972-74-710-7131 Cell: +972-54-674-5580 MATAM Park, Building 20, Haifa 31905, Israel firstname.lastname@example.org